Inhalable Drugs Market (2026 - 2033)

Inhalable Drugs Market Summary

The global inhalable drugs market size was valued at USD 38.0 billion in 2025 and is projected to grow from USD 40.3 billion in 2026 to USD 63.3 billion by 2033, at a CAGR of 6.7% from 2026 to 2033. The market in North America dominated with a revenue share of 41.2% in 2025. The increasing prevalence of respiratory diseases such as Chronic Obstructive Pulmonary Disease (COPD), asthma, and cystic fibrosis is anticipated to boost market growth.

According to the Centers for Disease Control and Prevention (CDC), more than 25 million people had asthma in the U.S. in 2021, accounting for approximately 8.0% of adults and 6.5% of children. The increasing prevalence of non-respiratory diseases such as diabetes and Parkinson’s disease is a key factor expected to fuel the market for inhalable drugs. Parkinson’s disease is widely reported in people aged 60 years and above. The prevalence rate of this disease increases with age.

According to an article released by the World Health Organization in October 2022, globally, the percentage of individuals aged 60 years and above is likely to increase twofold from 12% in 2015 to 22% by 2050. Therefore, manufacturers are developing inhalable drugs for ease of administration in the geriatric population. For instance, in December 2018, INBRIJA, a prescription medicine containing levodopa, was approved by the U.S. Food and Drug Association (FDA) for adults.

Advancements in inhalable drugs are expected to propel market growth. Advanced inhalation therapy involves using surfactant carriers, nanocrystals, and micro and nanoparticles. Therefore, research is conducted on small molecules to develop innovative inhalable drugs. These advancements in inhalation therapies offer increased systemic availability of drugs, convenience over invasive methods, improved drug interactions, and minimal toxicities. Reformulation of existing non-inhaled molecules into inhaled molecules for enhanced delivery of the drug is providing new growth opportunities to market players. For instance, the reformulation of dihydroergotamine (intravenous drug) into mesylate salt breath-actuated MDI device (Tempo) to treat migraine.

The strong presence of leading players in the field will continue to benefit the global market. These companies focus on unmet market needs, geographic expansion objectives, developing innovative products, and mergers and acquisitions to capitalize on their market share. These companies also provide services to various entities to improve the quality of drug delivery systems and patient compliance. Moreover, the need for efficient therapies and competition among new market players is expected to provide growth potential in inhalable drugs. Furthermore, these players focus on personnel training and R&D investments to capture a larger market share.

Market Dynamics

The inhalable drugs market is driven by the increasing prevalence of respiratory disorders such as asthma, chronic obstructive pulmonary disease, cystic fibrosis, and pulmonary infections. Inhalation remains a preferred route of administration for respiratory therapies because it enables direct drug delivery to the lungs and supports rapid therapeutic action while reducing systemic exposure. The market is also supported by the growing use of dry powder inhalers, metered dose inhalers, and nebulized formulations across both chronic and acute care. Pharmaceutical companies are expanding inhaled drug portfolios through product approvals, generic launches, and device improvements aimed at enhancing dose consistency and patient adherence. In addition, research activities focused on inhaled biologics, vaccines, and systemic drug delivery are broadening the scope of inhalation based therapies. Regulatory support for generic inhalation products and continued efforts to improve access to respiratory treatments are contributing to market expansion across developed and emerging healthcare markets.

Analyst Perspective

The inhalable drugs market is evolving from a respiratory focused treatment segment into a broader drug delivery platform, supported by advances in inhaler technologies, formulation development, and pulmonary drug delivery science. The market is increasingly centered around companies with established respiratory portfolios, inhalation device expertise, and global manufacturing capabilities. AstraZeneca and GSK continue to maintain strong positions through their extensive portfolios of asthma and COPD therapies, while Boehringer Ingelheim remains a key participant with its long standing presence in respiratory care. Viatris and Cipla are strengthening competition through the expansion of generic inhalation products and broader access to respiratory treatments. At the same time, companies such as Vectura Group and Mundipharma are contributing through inhalation technology development and specialized delivery platforms. The growing application of inhaled therapies beyond traditional respiratory diseases, including systemic and specialty indications, is further supporting product development and expanding the role of inhalable drugs across multiple therapeutic areas.

Drug Class Insights

The dry powder formulation segment accounted for the largest revenue share of 55.7% in 2025 and is expected to grow at the fastest CAGR during the forecast period. The segment's growth is attributed to its higher efficacy and better results compared with other forms. Furthermore, a wide range of products and a strong pipeline for this formulation are factors responsible for its dominant market share. In June 2022, United Therapeutics Corporation announced that the FDA had approved Tyvaso DPI, an inhalation powder for treating pulmonary arterial hypertension and pulmonary hypertension linked with interstitial lung diseases.

The focus of manufacturers on developing small-sized particle products has increased, which is expected to fuel the market growth during the forecast period. For instance, in April 2019, Cipla launched Niveoli-the first extra-fine particle inhaler developed in India. The inhaler comprises beclomethasone-formoterol and hydrofluoroalkane (HFA), which ensures targeted delivery to small airways in asthma and COPD patients.

Aerosols are expected to witness steady growth over the forecast period owing to their user-friendliness. Players are constantly looking to manufacture inhalable products that are easy to use and effective without being too complicated. For instance, in February 2018, Teva Pharmaceuticals launched the QVAR RediHaler inhalation aerosol in the U.S. as a tool for asthma management.

Application Insights

Based on application, the respiratory diseases segment led the market with the largest revenue share of 83.5% in 2025. Inhalable drugs are widely used to treat chronic respiratory diseases such as asthma, COPD, bronchospasm, and non-respiratory diseases such as diabetes and Parkinson’s. Combination therapy of Inhaled Corticosteroid (ICS), Long-Acting Muscarinic Antagonist (LAMA), and Long-Acting β2 Adrenoceptor Agonist (LABA) are extensively used for the treatment of COPDs and asthma due to their effectiveness, ability to reduce inflammation of lungs, and less need for hospitalization.

The effectiveness of these drugs has driven many manufacturers to develop combination therapies. For instance, in September 2020, GlaxoSmithKline plc and Innoviva, Inc. announced that the FDA had approved a new indication for combination therapy Trelegy Ellipta for the treatment of asthma in patients aged 18 years and above, expanding on its existing license to treat COPD patients.

The non-respiratory diseases material segment is estimated to register the fastest CAGR of 8.0% over the forecast period. Due to the rising prevalence of diabetes and the high cost of medications, manufacturers have devised an inhaler as an alternative therapy with reduced cost. For instance, in January 2019, MannKind Corporation developed and commercialized Afrezza for patients with diabetes. The company started a direct purchase program for inhalable insulin Afrezza for as little as USD 4 per day.

Regional Insights

North America dominated the inhalable drugs market with the largest revenue share of 41.2% in 2025, followed by Europe. Both the markets for inhalable drugs are fueled by various awareness programs conducted by governments, organizations, and companies to improve treatment options for COPD. For instance, in November 2021, the Emphysema Foundation of America launched COPD Awareness Campaign. The campaign aims to educate and equip those with COPD, their families, and carers to recognize and lessen the effects of the disease.

U.S. Inhalable Drugs Market Trends

The U.S. inhalable drugs market represented the largest share of the North American market in 2025, supported by the country’s well-established respiratory healthcare infrastructure, high prevalence of chronic respiratory conditions, and broad adoption of inhalation-based therapies. The presence of a large patient population suffering from asthma, chronic obstructive pulmonary disease (COPD), and other pulmonary disorders continues to sustain demand for inhalable medicines. The U.S. market is also supported by the availability of advanced inhalation products, including aerosol-based inhalers, dry powder formulations, and nebulized therapies. Strong pharmaceutical company presence, extensive product portfolios, established distribution networks, and continued investment in inhalation drug development further reinforce the country’s position within the region. In addition, regulatory approvals, generic product launches, and growing access to specialized respiratory treatments contribute to market expansion. These factors collectively enable the U.S. to maintain its leading position in North America during the forecast period. 

Asia Pacific Inhalable Drugs Market Trends

Asia Pacific is expected to grow at the fastest CAGR of 6.9% during the forecast period. This growth can be attributed to improving healthcare infrastructure, rising patient awareness, and increasing disposable income. Moreover, new market entrants are expected to play an important role in providing a growth platform to this regional market over the next few years. Growing medical tourism in several Asian countries is also attracting the attention of leading global players to set up numerous emerging economies with significant growth potential.

Key Companies & Market Share Insights

The key players operating in the inhalable drugs market are involved in developing and launching novel products and undertaking strategic initiatives to gain a competitive edge. More than 220 projects regarding inhalable medicines are currently in progress worldwide. For instance, Breath Therapeutics’ Boston Program focusing on developing Cyclosporine A for Inhalation to treat Bronchiolitis Obliterans Syndrome is in Phase III clinical trial. It is expected to be launched during the forecast period. They also engage in joint ventures, collaborative development, mergers, and acquisitions.

In January 2023, AstraZeneca received approval from the U.S. Food and Drug Administration for Airsupra (albuterol and budesonide) inhalation aerosol. Airsupra aims to reduce the risk of asthma exacerbations in individuals aged 18 years and older. The inhalable drug is co-developed by AstraZeneca and Avillion. In addition, in March 2022, Viatris Inc. and Kindeva Drug Delivery L.P. received FDA approval for Breyna, a drug-device combination therapy recommended for patients with asthma or chronic obstructive pulmonary disease (COPD). Furthermore, in August 2018, Glenmark Pharmaceuticals entered a licensing agreement to commercialize Tiotropium Bromide dry powder inhaler to treat COPD in Europe.

Key Inhalable Drugs Companies:

The following key companies have been profiled for this study on the inhalable drugs market:

• AstraZeneca

• Sanofi

• Vectura Group Ltd

• Viatris Inc.

• GSK plc.

• Mundipharma International.

• Boehringer Ingelheim International GmbH.

• Cipla Inc.

Competitive Benchmarking

Inhalable Drugs Market Report Scope

Global Inhalable Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global inhalable drugs market based on drug class, application, and region:

• Drug Class Outlook (Revenue, USD Million, 2021 - 2033)

  • Aerosol

  • Dry powder formulation

  • Spray

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Respiratory diseases

  • Non-respiratory disease

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The inhalable drugs market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing - reconciling supply-side and demand-side estimates - and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each inhalable drugs segment quantified using the revenue-capture definitions in the table below.

Segment Definition

Estimation Model

The inhalable drugs market was estimated using a commodity flow and revenue based market analysis approach. The methodology began with the identification of key manufacturers and commercially available inhalable therapies across aerosol, dry powder formulation, and spray based delivery systems. Major inhaled drug categories used for respiratory and non-respiratory indications were benchmarked based on annual sales, prescription volumes, product pricing, distribution channels, and geographic presence. Revenue generated from leading inhalable products was assessed using company annual reports, investor presentations, regulatory filings, healthcare databases, prescription audits, and industry publications. Product level revenues were aggregated to estimate market revenues across different drug classes, applications, and distribution channels.

The market estimates were further validated through an assessment of the patient population receiving inhaled therapies for conditions such as asthma, chronic obstructive pulmonary disease, cystic fibrosis, pulmonary hypertension, diabetes, and other chronic disorders. Treatment utilization rates, prescription patterns, and product adoption trends across hospitals, retail pharmacies, and online pharmacies were analyzed to determine demand side dynamics. Data triangulation was performed by comparing manufacturer revenues, prescription volumes, and treatment rates to ensure consistency across market estimates. Forecast projections incorporated disease prevalence trends, product innovation, regulatory approvals, treatment adoption rates, and the expansion of inhaled therapies into non respiratory indications.

Delivered Customizations

This report has been delivered with the following In-depth customizations